2026
Preclinical Studies Completion
BioRegenics, Inc., expects to complete preclinical studies for BioAct Matrix in both the femoral defect and spinal fusion models, combined with biocompatibility in 2026
Submit 510K Application to FDA
BioRegenics plans to submit device package for bone void filler for skeletal defects as well as spinal fusions in 2026